Cargando…

Plasma α‐synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson’s disease

The use of a diagnostic panel comprising multiple biomarkers has the potential to accurately diagnose Parkinson’s disease (PD). However, a panel consisting solely of plasma biomarkers to diagnose PD is not available. This study aimed to examine the diagnostic ability of plasma biomarker panels for d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Jingru, Pan, Chenxi, Wang, Yajie, Xue, Chen, Lin, Huixia, Xu, Jianxia, Wang, Hui, Zhang, Wenbin, Xu, Pingyi, Chen, Yong, Liu, Weiguo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314946/ https://www.ncbi.nlm.nih.gov/pubmed/35234288 http://dx.doi.org/10.1111/jnc.15601

Ejemplares similares

Consistency and Stability of Motor Subtype Classifications in Patients With de novo Parkinson’s Disease
por: Ren, Jingru, et al.
Publicado: (2021)

Altered Dynamic Functional Connectivity in de novo Parkinson’s Disease Patients With Depression
por: Xu, Jianxia, et al.
Publicado: (2022)

Non-Motor Symptoms of the Postural Instability and Gait Difficulty Subtype in De Novo Parkinson’s Disease Patients: A Cross-Sectional Study in a Single Center
por: Ren, Jingru, et al.
Publicado: (2020)

Prevalence and genotype–phenotype correlations of GBA‐related Parkinson disease in a large Chinese cohort
por: Ren, Jingru, et al.
Publicado: (2022)

Comparison of Three Motor Subtype Classifications in de novo Parkinson's Disease Patients
por: Ren, Jingru, et al.
Publicado: (2020)

Functional and structural alterations as diagnostic imaging markers for depression in de novo Parkinson’s disease
por: Wang, Hui, et al.
Publicado: (2023)

Altered Neural Network Connectivity Predicts Depression in de novo Parkinson’s Disease
por: Xu, Jianxia, et al.
Publicado: (2022)

Editorial: Biomarkers and Pathogenesis of Alpha-Synuclein in Parkinson's Disease
por: Li, Puyu, et al.
Publicado: (2021)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Phosphorylation of Tau and α-Synuclein Induced Neurodegeneration in MPTP Mouse Model of Parkinson’s Disease
por: Hu, Shanshan, et al.
Publicado: (2020)

Plasma phosphorylated tau181 predicts cognitive and functional decline
por: Tropea, Thomas F., et al.
Publicado: (2022)

Serum miR-214 Serves as a Biomarker for Prodromal Parkinson’s Disease
por: Li, Lanting, et al.
Publicado: (2021)

Correlation between cognitive impairment and serum phosphorylated tau181 protein in patients with preeclampsia
por: Wang, Yuanyuan, et al.
Publicado: (2023)

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
por: Shen, Xue-Ning, et al.
Publicado: (2021)

Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer’s disease
por: Chen, Shi-Dong, et al.
Publicado: (2021)

Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism
por: Taymans, Jean-Marc, et al.
Publicado: (2014)

Phosphorylated Tau 181 Serum Levels Predict Alzheimer’s Disease in the Preclinical Stage
por: Qin, Wei, et al.
Publicado: (2022)

Estimation of Tau and Phosphorylated Tau(181) in Serum of Alzheimer’s Disease and Mild Cognitive Impairment Patients
por: Shekhar, Shashank, et al.
Publicado: (2016)

The Role of α-Synuclein and LRRK2 in Tau Phosphorylation
por: Kawakami, Fumitaka, et al.
Publicado: (2015)

Characterizing mild cognitive impairment in prodromal Parkinson’s disease: A community‐based study in China
por: Pan, Chenxi, et al.
Publicado: (2021)

Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
por: Moscoso, Alexis, et al.
Publicado: (2020)

Alterations of Erythrocytic Phosphorylated Alpha-Synuclein in Different Subtypes and Stages of Parkinson's Disease
por: Li, Xu-Ying, et al.
Publicado: (2021)

Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer’s disease: a systematic review and meta-analysis
por: Ding, Xulong, et al.
Publicado: (2021)

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration
por: Thijssen, Elisabeth H., et al.
Publicado: (2020)

Erratum to: Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
Publicado: (2021)

Reference intervals for plasma amyloid-β, total tau, and phosphorylated tau181 in healthy elderly Chinese individuals without cognitive impairment
por: Chen, Jingshan, et al.
Publicado: (2023)

Plasma Phosphorylated-tau181 Is a Predictor of Post-stroke Cognitive Impairment: A Longitudinal Study
por: Huang, Li-Kai, et al.
Publicado: (2022)

Subjective Cognitive Complaints in Newly-Diagnosed Parkinson’s Disease With and Without Mild Cognitive Impairment
por: Pan, Chenxi, et al.
Publicado: (2021)

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease
por: Moscoso, Alexis, et al.
Publicado: (2021)

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome
por: Lleó, Alberto, et al.
Publicado: (2021)

Elevation of plasma phosphorylated tau181 during neurological illnesses affecting consciousness and kidney dysfunction
por: Thanapornsangsuth, Poosanu, et al.
Publicado: (2022)

Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease
por: Batzu, Lucia, et al.
Publicado: (2022)

Aberrant inter-network functional connectivity in drug-naive Parkinson’s disease patients with tremor dominant and postural instability and gait difficulty
por: Wang, Qi, et al.
Publicado: (2023)

AMI, an Indazole Derivative, Improves Parkinson’s Disease by Inhibiting Tau Phosphorylation
por: Mao, Zhang, et al.
Publicado: (2020)

Longitudinal Alterations of Alpha-Synuclein, Amyloid Beta, Total, and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease
por: Dolatshahi, Mahsa, et al.
Publicado: (2018)

Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease
por: Llibre-Guerra, Jorge J., et al.
Publicado: (2019)

Phosphorylated α-synuclein in diluted human serum as a biomarker for Parkinson's disease
por: Chen, Wei-Ru, et al.
Publicado: (2022)

Optimization of the Detection Method for Phosphorylated α-Synuclein in Parkinson Disease by Skin Biopsy
por: Liu, Xiaojing, et al.
Publicado: (2020)

Altered functional connectivity of the primary motor cortex in tremor dominant and postural instability gait difficulty subtypes of early drug-naive Parkinson’s disease patients
por: Wang, Qi, et al.
Publicado: (2023)

Prevalence and affective correlates of subjective cognitive decline in patients with de novo Parkinson's disease
por: Yang, Ning, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8nq02cj6hfh9ecge7n7paquuvv